Andrea Gropman, MD, FAAP, FACMG, FANA, is Division Chief of Neurodevelopmental Disabilities and Neurogenetics at the Children's National Hospital and the Principle investigator of the Urea Cycle Disorders Consortium. She is also the deputy clinical director of the Mito EpiGen research collaborative and Director of the Clinical Translational Core of the Intellectual Disabilities and Developmental Disabilities Research Center at CNH. She is fellowship trained and board certified in neurology/child neurology, clinical and biochemical genetics, and developmental disabilities. In August of 2006, she joined the neurology department of Children's National Medical Center and the George Washington University School of Medicine and in 2013 was promoted to professor with tenure. Dr. Gropman's research interest focuses on establishing biomarkers of neurological injury in patients with inborn errors of metabolism such as urea cycle disorders and mitochondrial disorders using specialized multimodal neuroimaging and cell markers. She has dedicated the last 15 years of her career towards translational research to better characterize and understand the underpinnings of neurological injury in urea cycle disorders, their impact on complex cognitive functions and establishing neuromonitoring protocols that can be implemented universally in clinical settings to improve patient outcomes and quality of life. She is also very involved in understanding the neurocognitive phenotypes of several chromosome disorders such as Smith Magenis syndrome and the X,Y chromosomes disorders. Her research and clinical involvement in these conditions has spanned over 20 years of her career.